Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 12, 2007, Pages 1334-1338

  Shishido, Yuichiro ^a,d   Mitarai, S ^b   Otomo, K ^b   Seki, M ^c   Sato, A ^c   Yano, I ^c   Koyama, A ^c   Hattori, T ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^c Kiyose   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

BCG; Drug susceptibility; Minimum inhibitory concentration

Indexed keywords

BCG VACCINE; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; BACILLUS CALMETTE GUERIN VACCINE INFECTION; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG SAFETY; DRUG SENSITIVITY; IMMUNOCOMPROMISED PATIENT; INFECTION COMPLICATION; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; BCG VACCINE; ETHAMBUTOL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS;

EID: 37549026466     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. World Health Organization. WHO report 2005. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2005.349. Geneva, Switzerland: WHO, 2005.
2. Landi S, Barbara C, Przykuta K, Held H R. Comparison of freeze-dried vaccines prepared from four different strains of BCG. Dev Biol Stand 1977; 38: 19-28.
3. Okazaki T, Ebihara S, Takahashi H, Asada M, Sato A, Seki M. Multiplex PCR-identified cutaneous tuberculosis evoked by Mycobacterium bovis BCG vaccination in a healthy baby. J Clin Microbiol 2005; 43: 523-525.
4. Su W J, Huang C Y, Huang C Y, Perng R P. Utility of PCR assays for rapid diagnosis of BCG infection in children. Int J Tuberc Lung Dis 2001; 5: 380-384.
5. Albrecht H, Stellbrink H J, Eggers C, Rusch-Gerdes S, Greten H. A case of disseminated Mycobacterium bovis infection in an AIDS patient. Eur J Clin Microbiol Infect Dis 1995; 14: 226-229.
6. Heifets L B. Drug susceptibility in the chemotherapy of mycobacterial infections. London, UK: CRC Press, 1991.
7. National Committee for Clinical Laboratory Standards (NCCLS). Susceptibility testing of Mycobacterium tuberculosis, Nocardiae, and other aerobic Actinomycetes: approved standard. NCCLS document M-24A. Vol 23, no 18. Wayne, PA, USA: NCCLS, 2003.
8. Trunz B B, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-1180.
9. McKenzie R H, Roux P. Disseminated BCG infection following bone marrow transplantation for X-linked severe combined immunodeficiency. Pediatr Dermatol 2000; 17: 208-212.
10. Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41: 1049-1052.
11. Morales A, Eidinger D, Bruce A W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-183.
12. Debois H, Loupi E, Saliou P. Surveillance of the safety of intravesical BCG therapy in France: quantitative analysis of serious adverse events notified over a period of five years. Prog Urol 2002; 12: 604-608. (in French)
13. Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus Calmette-Guérin Tokyo 172 substrain for superficial bladder cancer: characterization and antitumor effect. J Urol 2005; 173: 1507-1512.
14. Mugiya S, Ozono S, Nagata M, et al. Long-term outcome of a low-dose intravesical bacillus Calmette-Guérin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005; 35: 395-399.
15. Eichel L, Erturk E, Disant'Agnese A. Drug resistant Mycobacterium bovis cystitis following intravesical bacillus Calmette-Guérin treatment. J Urol 1999; 162: 2096.
16. Durek C, Rusch-Gerdes S, Jocham D, Bohle A. Sensitivity of BCG to modern antibiotics. Eur Urol 2000; 37 (Suppl): S21-S25.
17. Durek C, Rusch-Gerdes S, Jocham D, Bohle A. Interference of modern antibacterials with bacillus Calmette-Guérin viability. J Urol 1999; 162: 1959-1962.
18. Rousseau P, Dupuis M. Antituberculous drug susceptibility testing of Mycobacterium bovis BCG strain Montreal. Can J Microbiol 1990; 36: 735-737.
19. Otten H. Ethambutol (EMB). In: Bartmann K, ed. Anti-tuberculosis drugs. Berlin, Germany: Springer-Verlag 1988: pp 197-204.
20. Rastogi N, Labrousse V, Goh K S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-175.
21. Suo J, Chang C E, Lin T P, Heifets L B. Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan. Am Rev Respir Dis 1988; 138: 999-1001.
22. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 1988; 137: 1217-1222.
23. Holdiness M R. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9: 511-544.
24. Hesseling A C, Schaaf H S, Victor T, et al. Resistant Mycobacterium bovis bacillus Calmette-Guérin disease: implications for management of bacillus Calmette-Guérin disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23: 476-479.
25. Mahairas G G, Sabo P J, Hickey M J, Singh D C, Stover C K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178: 1274-1282.
26. Pym A S, Brodin P, Brosch R, Huerre M, Cole S T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002; 46: 709-717.
27. Behr M A, Wilson M A, Gill W P, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-1523.
28. Sørensen A L, Nagai S, Houen G, et al. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995; 63: 1710-1717.
29. Berthet F X, Rasmussen P B, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998; 144: 3195-3203.
30. Hesselberg I. Drug resistance in the Swedish/Norwegian BCG strain. Bull World Health Organ 1972; 46: 503-507.
31. Knezevic I, Corbel M J. WHO discussion on the improvement of the quality control of BCG vaccines. Pasteur Institute, Paris, France, 7 June 2005. Vaccine 2006; 24: 3874-3877.